- Home
- KRMD vs MIRM Comparison
KRMD vs MIRM Comparison
Compare KRMD & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRMD | MIRM |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.5M | 7.2B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KRMD | MIRM |
|---|---|---|
| Price | $3.22 | $98.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $6.50 | ★ $119.85 |
| AVG Volume (30 Days) | 155.4K | ★ 420.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.85 | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,127,366.00 | $19,138,000.00 |
| Revenue This Year | $20.32 | $26.22 |
| Revenue Next Year | $17.37 | $22.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $3.12 | $63.23 |
| 52 Week High | $6.61 | $130.00 |
Technical Indicators
Market Signals| Indicator | KRMD | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 31.93 | 50.89 |
| Support Level | N/A | $88.08 |
| Resistance Level | $3.43 | $105.20 |
| Average True Range (ATR) | 0.10 | 3.49 |
| MACD | 0.02 | 0.35 |
| Stochastic Oscillator | 17.65 | 70.89 |
Price Performance
Historical ComparisonAbout KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.